Glucotrack has successfully completed its first in-human clinical study for the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein.

The company’s system is placed in the subclavian vein, a blood vessel that runs under the collar bone bringing deoxygenated ...

Glucotrack (GCTK) reports successful completion of first human clinical study for continuous blood glucose monitoring, shares ...

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose ...

Paul V. Goode, President and Chief Executive Officer, will give a corporate update on the Company’s Continuous Blood Glucose Monitor (CBGM). TechBio Showcase, as part of Biotech Showcase ...

ISO 13485 is also strongly recommended and widely used in the European Union. For more information about Glucotrack's CBGM, visit glucotrack.com . Information on the Company's website does not ...

"I am honored to join the Company at this pivotal time as we advance our human clinical trials and create a strategic regulatory program for the CBGM," Williams stated regarding his new role at ...

This study represents the first real-time, continuous blood glucose monitor (CBGM) placed in the subclavian vein, offering the potential for direct blood glucose measurement without the limitations ...

Paul V. Goode, President and Chief Executive Officer, will give a corporate update on the Company’s Continuous Blood Glucose Monitor (CBGM). TechBio Showcase, as part of Biotech ...

Presentation to feature an update on the Company's novel continuous blood glucose monitor for patients with diabetes RUTHERFORD, N.J., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) ...